Skip to Content
Merck
CN

P0968

Sigma-Aldrich

Monoclonal Anti-p16INK4a/CDKN2 antibody produced in mouse

clone DCS-50, ascites fluid

Sign Into View Organizational & Contract Pricing

Select a Size


About This Item

MDL number:
UNSPSC Code:
12352203
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

biological source

mouse

conjugate

unconjugated

antibody form

ascites fluid

clone

DCS-50, monoclonal

mol wt

antigen 16 kDa

contains

15 mM sodium azide

species reactivity

human

technique(s)

immunocytochemistry: suitable
immunohistochemistry (frozen sections): suitable
immunoprecipitation (IP): suitable
indirect ELISA: suitable
microarray: suitable
western blot: 1:1,000 using a cultured human tumor cell line extract

isotype

IgG1

shipped in

dry ice

storage temp.

−20°C

Gene Information

human ... CDKN2A(1029)

Immunogen

recombinant human p16 protein.

Biochem/physiol Actions

The antibody reacts specifically with the C-terminal (last 12 amino acids) of human p16 molecule (also known as p16INK4, p16INK4a, p16MTS1, inhibitor of CDK4). An additional application for this antibody is microinjection into cells.

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

J Lukas et al.
Cancer research, 55(21), 4818-4823 (1995-11-01)
The p16INK4/CDKN2, D-type cyclins, their partner cyclin-dependent kinases, and retinoblastoma protein constitute a G1 regulatory pathway commonly targeted in oncogenesis. We show that, unexpectedly, abnormalities of p16INK4/CDKN2 occur concomitantly in two-thirds of cancer cell lines harboring aberrations of cyclin D1.
J Lukas et al.
Nature, 375(6531), 503-506 (1995-06-08)
D-type cyclins, in association with the cyclin-dependent kinases Cdk4 or Cdk6, promote progression through the G1 phase of the cell cycle by phosphorylating the retinoblastoma protein (RB). The activities of Cdk4 and Cdk6 are constrained by inhibitors such as p16
A L Reed et al.
Cancer research, 56(16), 3630-3633 (1996-08-15)
The tumor suppressor gene p16 (CDKN2/MTS-1/INK4A) can be inactivated by multiple genetic mechanisms. We analyzed 29 invasive primary head and neck squamous cell carcinomas (HNSCC) for p16 inactivation with immunohistochemistry utilizing a new monoclonal antibody (mAb), DCS-50. p16 staining of
L Aagaard et al.
International journal of cancer, 61(1), 115-120 (1995-03-29)
The p16Ink4/MTS1/CDKN2 is a cell-cycle regulatory inhibitor of cyclin-dependent kinase 4 (cdk4), and a candidate tumour suppressor whose gene on chromosome band 9p21 is frequently deleted or mutated in diverse types of cancer. Cdk4 in association with its D-type cyclin
Ji-Seon Lee et al.
Stem cells (Dayton, Ohio), 27(8), 1963-1975 (2009-06-23)
Human mesenchymal stem cells (hMSCs) have been widely studied as a source of primary adult stem cells for cell therapy because of their multidifferentiation potential; however, the growth arrest (also known as "premature senescence") often found in hMSCs cultured in

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service